Literature DB >> 19277788

Liver resection with portal vein thrombectomy for hepatocellular carcinoma with vascular invasion.

Luca Aldrighetti1, Carlo Pulitanò, Marco Catena, Marcella Arru, Eleonora Guzzetti, Jane Halliday, Gianfranco Ferla.   

Abstract

INTRODUCTION: Hepatocellular carcinoma (HCC) tends to invade the intrahepatic vasculature, especially the portal vein. The presence of portal vein tumor thrombus (PVTT) in patients with HCC is one of the most significant factors for a poor prognosis. The presence of macroscopic PVTT in patients with HCC is also a significant factor for poor prognosis, with a median survival of <3 months without treatment. In surgically resected series, in patients with gross PVTT (PVTT in the portal trunk, its first-order branch, or its second-order branch), the 3-year and 5-year survival rates are reportedly 15% to 28% and 0% to 17%, respectively.
METHODS: The patient was a 77-year-old woman with well-compensated hepatitis C virus-related cirrhosis (stage A6 according to Child-Pugh classification) who sought care at our department for vague abdominal discomfort. Triphasic spiral computed tomographic scan confirmed HCC 6 cm in diameter in the left lobe of the liver. In addition, portal vein tumor thrombosis of the left branch that extended to the right portal vein was present.
RESULTS: The procedure included left hepatectomy and en-bloc portal vein thrombectomy with clamping of both the common portal vein trunk and the right portal vein. The portal vein was incised at the bifurcation of the right and left portal veins, and the thrombus was extracted from the incision in the portal vein. With this procedure, we were able to examine under direct vision the exact extent of the portal vein thrombus, and we identified whether the tumor thrombus was adherent to the venous wall or was freely floating in the venous lumen. Portal clamping and length of operation were 16 and 330 minutes, respectively. Intraoperative blood loss was 550 mL. The patient was discharged on postoperative day 6, and she was free of disease at 15 months after surgery. DISCUSSION: Liver resection should be considered a valid therapeutic option for HCC with PVTT.

Entities:  

Mesh:

Year:  2009        PMID: 19277788     DOI: 10.1245/s10434-009-0383-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  16 in total

1.  Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging.

Authors:  Tian Yang; Chuan Lin; Jian Zhai; Song Shi; Min Zhu; Nan Zhu; Jun-Hua Lu; Guang-Shun Yang; Meng-Chao Wu
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-10       Impact factor: 4.553

2.  Chromatin remodeling factor ARID2 suppresses hepatocellular carcinoma metastasis via DNMT1-Snail axis.

Authors:  Hao Jiang; Hui-Jun Cao; Ning Ma; Wen-Dai Bao; Jing-Jing Wang; Tian-Wei Chen; Er-Bin Zhang; Yan-Mei Yuan; Qian-Zhi Ni; Feng-Kun Zhang; Xu-Fen Ding; Qian-Wen Zheng; Yi-Kang Wang; Min Zhu; Xiang Wang; Jing Feng; Xue-Li Zhang; Shu-Qun Cheng; Dan-Jun Ma; Lin Qiu; Jing-Jing Li; Dong Xie
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-18       Impact factor: 11.205

3.  Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma.

Authors:  Jia-Yan Ni; Hong-Liang Sun; Yao-Ting Chen; Jiang-Hong Luo; Dong Chen; Xiong-Ying Jiang; Lin-Feng Xu
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

4.  Characterisation of a novel cell line (CSQT-2) with high metastatic activity derived from portal vein tumour thrombus of hepatocellular carcinoma.

Authors:  T Wang; H S Hu; Y X Feng; J Shi; N Li; W X Guo; J Xue; D Xie; S R Liu; M C Wu; S Q Cheng
Journal:  Br J Cancer       Date:  2010-05-11       Impact factor: 7.640

5.  Efficacy of a hepatectomy and a tumor thrombectomy for hepatocellular carcinoma with tumor thrombus extending to the main portal vein.

Authors:  Daisuke Ban; Kazuaki Shimada; Yusuke Yamamoto; Satoshi Nara; Minoru Esaki; Yoshihiro Sakamoto; Tomoo Kosuge
Journal:  J Gastrointest Surg       Date:  2009-09-02       Impact factor: 3.452

6.  An aggressive approach leads to improved survival in hepatocellular carcinoma patients with portal vein tumor thrombus.

Authors:  De-Xin Lin; Qi-Yu Zhang; Xuan Li; Qi-Wen Ye; Fen Lin; Lin-Li Li
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-26       Impact factor: 4.553

7.  Surgical Strategy for Hepatocellular Carcinoma Patients with Portal/Hepatic Vein Tumor Thrombosis.

Authors:  Li Shaohua; Wang Qiaoxuan; Sun Peng; Li Qing; Yang Zhongyuan; Shi Ming; Wei Wei; Guo Rongping
Journal:  PLoS One       Date:  2015-06-15       Impact factor: 3.240

8.  A novel scoring system predicts adjuvant chemolipiodolization benefit for hepatocellular carcinoma patients after hepatectomy.

Authors:  Li-Feng Huang; Xianglei Xing; Dong Wu; Yong Xia; Jun Li; Kui Wang; Zhen-Lin Yan; Xu-Ying Wan; Le-Hua Shi; Tian Yang; Wan Yee Lau; Meng-Chao Wu; Feng Shen
Journal:  Oncotarget       Date:  2016-05-03

9.  Optimal surgical strategy for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score analysis.

Authors:  Yong-Fa Zhang; Yong Le; Wei Wei; Ru-Hai Zou; Jia-Hong Wang; Han-Yue OuYang; Cheng-Zuo Xiao; Xiao-Ping Zhong; Ming Shi; Rong-Ping Guo
Journal:  Oncotarget       Date:  2016-06-21

10.  Alcohol and hepatitis virus-dysregulated lncRNAs as potential biomarkers for hepatocellular carcinoma.

Authors:  Hao Zheng; Pinxue Li; James G Kwok; Avinaash Korrapati; Wei Tse Li; Yuanhao Qu; Xiao Qi Wang; Tatiana Kisseleva; Jessica Wang-Rodriguez; Weg M Ongkeko
Journal:  Oncotarget       Date:  2017-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.